Literature DB >> 3663788

Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects.

B Angrist1, J Corwin, B Bartlik, T Cooper.   

Abstract

Seven normal subjects received 0.25 mg/kg D-amphetamine orally, both after an overnight fast and again after a standard breakfast. Plasma levels, subjective and cardiovascular effects, and observer-rated activation were assessed hourly for 5 hr. Food did not affect amphetamine levels. Plasma levels peaked at 2-3 hr. Maximum cardiovascular effects generally occurred at 1 hr, whereas maximum behavioral and subjective effects occurred at 2 hr. Subjective and behavioral effects declined thereafter, in spite of substantial amphetamine levels. A separate group of 8 subjects received 0.5 mg/kg D-amphetamine orally. Plasma levels, subjective and cardiovascular effects, and activation ratings were assessed hourly for 4 hr. Maximum plasma levels were approximately twice those seen in the first group. In this case, plasma levels peaked at 3-4 hr; blood pressure and subjective and behavioral effects were all maximal at 2-3 hr and were declining by 4 hr, in spite of stable or rising plasma levels.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3663788     DOI: 10.1016/0006-3223(87)90070-9

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  33 in total

1.  Effects of monoaminergic drugs on training-induced motor cortex plasticity in older adults.

Authors:  Trisha M Kesar; Samir R Belagaje; Paola Pergami; Marc W Haut; Gerald Hobbs; Cathrin M Buetefisch
Journal:  Brain Res       Date:  2017-06-17       Impact factor: 3.252

2.  The effects of dexamphetamine on simulated driving performance.

Authors:  B Y Silber; K Papafotiou; R J Croft; E Ogden; P Swann; C Stough
Journal:  Psychopharmacology (Berl)       Date:  2004-12-22       Impact factor: 4.530

3.  Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges.

Authors:  Jonathan R Stevens; Timothy E Wilens; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-28

4.  Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects.

Authors:  Joshua A Lile; Shanna Babalonis; Cleeve Emurian; Catherine A Martin; Daniel P Wermeling; Thomas H Kelly
Journal:  J Clin Pharmacol       Date:  2010-07-29       Impact factor: 3.126

Review 5.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users.

Authors:  Katherine R Marks; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

7.  Relationship between discriminative stimulus effects and plasma methamphetamine and amphetamine levels of intramuscular methamphetamine in male rhesus monkeys.

Authors:  Matthew L Banks; Douglas A Smith; David F Kisor; Justin L Poklis
Journal:  Pharmacol Biochem Behav       Date:  2015-12-03       Impact factor: 3.533

Review 8.  Drug treatment for hyperactive children. Therapeutic guidelines.

Authors:  J Elia
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 9.  Neurocognitive enhancement or impairment? A systematic meta-analysis of prescription stimulant effects on processing speed, decision-making, planning, and cognitive perseveration.

Authors:  Marisa E Marraccini; Lisa L Weyandt; Joseph S Rossi; Bergljot Gyda Gudmundsdottir
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

10.  Acute d-amphetamine pretreatment does not alter stimulant self-administration in humans.

Authors:  William W Stoops; Andrea R Vansickel; Joshua A Lile; Craig R Rush
Journal:  Pharmacol Biochem Behav       Date:  2007-04-05       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.